Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Emory University
Emory University
Verastem, Inc.
BicycleTx Limited
Virginia Commonwealth University
National Cancer Institute (NCI)
Ningbo Medical Center Lihuili Hospital
ARTIDIS AG
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
City of Hope Medical Center
Pheon Therapeutics
Kivu Bioscience Inc.
Astellas Pharma Inc
University of California, San Francisco
Institut du Cancer de Montpellier - Val d'Aurelle
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Evopoint Biosciences Inc.
Washington University School of Medicine
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
Nammi Therapeutics Inc
National Cancer Institute (NCI)
Bristol-Myers Squibb
Incyte Corporation
Beijing Biotech
Jazz Pharmaceuticals
Bayer
NRG Oncology
Pfizer
University of California, San Diego
Pfizer
National Institutes of Health Clinical Center (CC)
Alpha Tau Medical LTD.
Revolution Medicines, Inc.
Revolution Medicines, Inc.
PanTher Therapeutics
Alterome Therapeutics, Inc.
EXACT Therapeutics AS
SONIRE Therapeutics Inc.
University of Massachusetts, Worcester